February 12, 2026 — Leads & Copy —
Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) has announced that the first participant has been dosed in BASECAMP, a Phase 2 pediatric study of SAT-3247 for Duchenne muscular dystrophy (DMD).
The three-month, randomized, double-blind, placebo-controlled, proof-of-concept study will evaluate SAT-3247 in 51 ambulatory children with DMD aged 7, 8 or 9 years of age. The company is a clinical-stage biotechnology company developing medicines to treat degenerative muscle diseases.
The study’s primary endpoints include safety, tolerability and effect on muscle force. Secondary endpoints will assess SAT-3247’s impact on muscle quality, function and regeneration.
According to Satellos Co-founder and CEO Frank Gleeson, BASECAMP is designed as a potential pivotal trial. Data generated from BASECAMP could play a meaningful role in accelerating the development of SAT-3247 as a treatment for Duchenne.
Satellos plans to establish 25 sites for the study at clinical centers in the United States, Europe, the United Kingdom, Australia, Canada and Serbia. The BASECAMP trial is actively enrolling participants.
According to Satellos Chief Medical Officer Wildon Farwell, treatment options remain limited for Duchenne, and this study will evaluate a novel approach to potentially increase muscle regeneration and thereby improve function among children with the disease.
SAT-3247 is a proprietary, oral, small molecule drug being developed by Satellos as a treatment to regenerate skeletal muscle that is lost in Duchenne and other degenerative or injury conditions. Satellos is advancing SAT-3247 as a potential treatment for DMD, independent of dystrophin and regardless of exon mutation status.
Satellos is focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Satellos has developed SAT-3247, a first-of-its-kind, orally administered small molecule drug designed to address deficits in muscle repair and regeneration. SAT-3247 targets AAK1, a key protein that Satellos has identified as capable of helping restore muscle stem cell signaling that is disrupted in DMD.
By addressing the loss of dystrophin-dependent cues, SAT-3247 may re-establish the signals that support effective muscle regeneration. SAT-3247 is currently in clinical development as a potential disease-modifying treatment, initially for DMD. Satellos is also working to identify additional muscle diseases or injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and represent future clinical development opportunities.
Source: Satellos Bioscience Inc.
